Prohibition Partners’ latest report on pharmaceutical cannabis has found combined sales of Epidyolex, Dronabinol and Sativex are set to reach EU$1.8 billion by 2025. 

The Pharmaceutical Cannabis Report: 2nd Edition notes that there are major opportunities for the use of cannabinoids in the treatment of medical conditions such as spasticity, PTSD, epileptic seizures and especially pain, with the current global spend on non-cannabinoid-based pain medications worldwide estimated at US$63-85 billion each year.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Avatar photo

Hannah Adler

Hannah is a communications professional and early-career researcher in the disciplines of health communication and health sociology. She is a PhD student at Griffith University currently writing a...

Leave a comment